

# A

\*click [HERE](#) for an explanation of standardised wording to be used by Scottish Boards regarding decisions on medicines since May 2016 [Link to Formulary](#)

Medicine	Indication	NHS Board Decision*	DTC Supplement	Date
5-aminolaevulinic acid (as hydrochloride) 78mg/g gel (Ameluz®) SMC No. (1260/17)	Treatment of superficial and / or nodular basal cell carcinoma (BCC) unsuitable for surgical treatment due to possible treatment-related morbidity and / or poor cosmetic outcome in adults.	Not available as not recommended for use in NHS Scotland	<a href="#">163</a> <a href="#">167</a>	Sep 2017 April 2018
Abacavir (Ziagen®)	HIV	Hospital Only	<a href="#">50</a>	2005
Abacavir/lamivudine (Kivexa®)	HIV	Hospital Only	<a href="#">50</a>	2005
Abatacept 125mg solution for injection (pre-filled syringe); 125mg solution for injection in pre-filled pen; 250mg powder for concentrate for solution for infusion (Orencia®) SMC No 1287/17	Alone or in combination with methotrexate for the treatment of active psoriatic arthritis in adult patients when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy including methotrexate has been inadequate, and for whom additional systemic therapy for psoriatic skin lesions is not required.	Not available as not recommended for use in NHS Scotland	<a href="#">165</a>	Jan 2018
Abatacept (Orencia®) (1230/17)	Treatment of highly active and progressive disease in adult patients with rheumatoid arthritis not previously treated with methotrexate.	Not available as not recommended for use in NHS Scotland	<a href="#">160</a>	Apr 2017
Abatacept (Orencia®) (888/13)	In combination with methotrexate, for the treatment of moderate to severe active rheumatoid arthritis in adult patients who responded inadequately to previous therapy with one or more disease-modifying anti-rheumatic drugs including methotrexate or a TNF-alpha inhibitor.	Hospital Only (4th line agent )	<a href="#">129</a>	Aug/Sep 2013
Abatacept (Orencia®) (618/10)	Juvenile idiopathic arthritis	Hospital Only (Paediatric Rheumatology Clinic)	<a href="#">112</a> <a href="#">96</a>	Dec 2011 Apr/May 2010

Abatacept (Orencia®) (719/11)	Moderate to severe active rheumatoid arthritis	Hospital Only	<a href="#">127</a> <a href="#">110</a> <a href="#">72</a>	May 2013 Oct 2011 Sep 2007
Abemaciclib 50mg, 100mg and 150mg film-coated tablets (Verzenios®) SMC2494	In combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. In pre- or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. In an open-label, randomised, phase III study, the addition of abemaciclib to adjuvant endocrine therapy improved invasive disease-free survival (IDFS) compared with endocrine therapy alone in patients with HR-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence. The cohort of study patients with at least four positive axillary lymph nodes or one to three positive axillary lymph nodes plus either grade 3 disease and/or tumour size ≥5cm supported the evidence for patients of high risk of recurrence in clinical practice.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	<a href="#">192</a>	Nov 22
Abemaciclib 50mg, 100mg and 150mg tablets (Verzenios®) SMC2135	For the treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor* as initial endocrine-based therapy, or in women who have received prior endocrine therapy.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	<a href="#">175</a>	Aug 2019
Abemaciclib 50mg, 100mg and 150mg tablets (Verzenios®) SMC2179	For the treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with fulvestrant* as initial endocrine-based therapy or in women who have received prior endocrine therapy.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	<a href="#">175</a>	Aug 2019

	SMC restriction: for use in women who have progressed on or after (neo) adjuvant endocrine therapy, or progressed during first-line endocrine-based therapy for advanced breast cancer			
Abiraterone (Zytiga®) (873/13)	With prednisone or prednisolone for the treatment of metastatic castration resistant prostate cancer in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.	Available in line with national guidance	<a href="#">146</a> <a href="#">127</a> <a href="#">152</a> <a href="#">157</a>	Feb 2015 May 2013 Nov/Dec 2015 Nov 2016
Abiraterone acetate 500mg film-coated tablets (Zytiga®) - SMC 2215	Abiraterone acetate with prednisone or prednisolone for the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer in adult men in combination with androgen deprivation therapy.	Approved in line with national guidance.	<a href="#">179</a>	Apr 2020
Abiraterone acetate 250mg tablets (Zytiga®)	With prednisone or prednisolone for treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.	Formulary Hospital Use only (Oncology)	<a href="#">153</a>	Jan/Feb 2016
Abiraterone acetate (Zytiga®) (764/12)	With prednisone or prednisolone for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.	Hospital Only (Oncology)	<a href="#">119</a> <a href="#">116</a>	Aug/Sept 2012 Apr/May 2012
Abrocitinib 50mg, 100mg, and 200mg film-coated tablets (Cibinqo®) SMC 2431	For the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. SMC restriction: for use in patients who have not responded to, or have lost response to, at least one systemic immunosuppressant therapy, or in whom these are contraindicated or not tolerated. Four phase III studies demonstrated superiority of	Available in line with local guidance for prescribing	<a href="#">190</a>	August 2022

	abrocitinib in improving signs and symptoms of atopic dermatitis when compared with placebo, as monotherapy or in combination with medicated topical therapies in patients with moderate to severe atopic dermatitis.			
Acalabrutinib 100mg hard capsules (Calquence®) SMC2347	As monotherapy or in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). SMC restriction: as monotherapy for the treatment of adult patients with previously untreated CLL without a del(17p) or TP53 mutation and who are ineligible for fludarabine, cyclophosphamide and rituximab (FCR) therapy	Available in line with national guidance	<a href="#">185</a>	July 2021
Acalabrutinib 100mg hard capsules (Calquence®) SMC2346	Indication under review: as monotherapy or in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). SMC restriction: as monotherapy for the treatment of adult patients with previously untreated CLL who have a 17p deletion or TP53 mutation and in whom chemo-immunotherapy is unsuitable. Acalabrutinib offers an additional treatment choice in the therapeutic class of Bruton tyrosine kinase inhibitor in this setting. Another medicine within this therapeutic class has been accepted via the end of life and orphan medicine process.	Available in line with national guidance	<a href="#">184</a>	May 2021
Acalabrutinib 100mg hard capsules (Calquence®) SMC2348	Indication under review: As monotherapy for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy. SMC restriction: For adults with relapsed/refractory CLL who have had at least one previous therapy, in whom chemo-immunotherapy is unsuitable. Acalabrutinib offers an additional treatment choice in the	Available in line with national guidance	<a href="#">184</a>	May 2021

	therapeutic class of BTK inhibitor in this setting. Another medicine within this therapeutic class has been accepted via the end of life and orphan medicine process.			
Acclidinium/formoterol fumarate dihydrate (Duaklir Genuair®) (1034/15)	Maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease.	Formulary	<a href="#">147</a>	Apr 2015
Acclidinium (Eklira Genuair®) (810/12)	COPD	Formulary	<a href="#">123</a> <a href="#">122</a>	Jan 2013 Dec 2012
Adalimumab 40mg/0.4mL pre-filled syringe and pre-filled pen / adalimumab 40mg/0.4mL 40mg/0.8mL vial for paediatric use (Humira®) SMC No 1305/18	Treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.	Not available as not recommended for use in NHS Scotland	<a href="#">167</a>	April 2018
Adalimumab, 40mg/0.4mL pre-filled syringe (Humira®) and pre-filled pen adalimumab, 40mg/0.8mL vial for paediatric use (Humira®) SMC No. (1243/17)	Treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa) in adolescents from 12 years of age with an inadequate response to conventional systemic HS therapy	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	<a href="#">162</a>	Aug 2017
Adalimumab 40mg/0.4ml Pre-filled Syringe and Pre-filled Pen & Adalimumab 40mg/0.8ml Pre-filled Syringe and Pre-filled Pen (Humira®) SMC 1209/16	Treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate	Not available as not recommended for use in NHS Scotland	<a href="#">158</a>	Dec 2016
Adalimumab 40mg/0.4ml Pre-filled Syringe and Pre-filled Pen & Adalimumab 40mg/0.8ml vial for paediatric use (Humira®) SMC 1208/16	Treatment of moderately active Crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies	Not available as not recommended for use in NHS Scotland	<a href="#">158</a>	Dec 2016

Adalimumab (Humira®) 1173/16	Treatment of moderate to severe chronic plaque psoriasis on adult patients who are candidates for systemic therapy. (This licence extension relates to previous SMC advice 468/08).	Not available as not recommended for use in NHS Scotland	<a href="#">156</a>	Sep 2016
Adalimumab 40mg/0.8ml solution for injection (Humira®) SMC 1143/16	Treatment of active moderate to severe hidradenitis suppurative (HS) (acne inversa) in adult patients with inadequate response to conventional HS therapy	Available in line with National guidance	<a href="#">155</a>	June 2016
Adalimumab (Humira®) (1050/15)	For the treatment of active enthesitis-related arthritis in patients, 6 years or age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy.	Hospital Use Only  (Paediatric Rheumatology) (Will not appear in TAF which is an adult formulary)	<a href="#">148</a>	May 2015
Adalimumab (Humira®) (1068/15)	Treatment of severe chronic plaquepsoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy andphototherapies.	Non Formulary  Lack of clinician demand	<a href="#">150</a>	June 2015
Adalimumab (Humira®) (880/13)	Severe active Crohn's disease (6 to 17 years)	Hospital Only (Paediatric Gastroenterology)	<a href="#">129</a>	Aug/Sep 2013
Adalimumab (Humira®) (881/13)	Active polyarticular juvenile idiopathic arthritis (2 to 17 years)	Hospital Only (Paediatric Rheumatology)	<a href="#">129</a>	Aug/Sep 2013
Adalimumab (Humira®) (858/13)	Severe axial spondyloarthritis	Hospital Only	<a href="#">127</a>	May 2013
Adalimumab (Humira®) (824/12)	Moderately active Crohn's disease	Not recommended	<a href="#">122</a>	Dec 2012
Adalimumab (Humira®) (800/12)	Ulcerative colitis	Not recommended	<a href="#">119</a>	Aug/Sep 2012
Adalimumab (Humira®) (738/11)	Active polyarticular juvenile idiopathic arthritis in children and adolescents (4-17 years)	Hospital Only (Paediatric Rheumatology Clinic)	<a href="#">112</a>	Dec 2011
Adalimumab (Humira®) (533/09)	Adolescents with active polyarticular juvenile idiopathic arthritis (13-17 years) in combination with methotrexate	Hospital Only (Paediatric Rheumatology Clinic)	<a href="#">86</a>	Jan 2009

Adalimumab (Humira®)	Chronic plaque psoriasis	Hospital Only	<a href="#">80</a>	June 2008
Adalimumab (Humira®) (417/07)	Severe, active Crohn's disease	Hospital Only (GI Clinic)	<a href="#">122</a> <a href="#">74</a>	Dec 2012 Nov 2007
Adalimumab (Humira®)	Severe active ankylosing spondylitis	Hospital Only (Rheumatology Clinic)	<a href="#">64</a>	2006
Adalimumab (Humira®)	Rheumatoid arthritis	Hospital Only (Rheumatology Clinic)	<a href="#">34</a>	2003
Adalimumab (Humira®)	Psoriatic arthritis	Hospital Only	<a href="#">55</a>	2006
Adapalene (Epiduo®) (682/11)	Acne vulgaris	Non-formulary - absence of clinician demand	<a href="#">137</a> <a href="#">104</a>	Apr/May 2014 Mar 2011
Adefovir (Hepsera®)	Chronic Hepatitis B	Hospital Only	<a href="#">50</a> <a href="#">29</a>	2005 2003
Adrenaline tartrate (Jext®) (687/11)	Severe acute allergic reactions	Formulary	<a href="#">111</a>	Nov 2011
Afamelanotide 16mg implant (Scenesse®) SMC (1251/17)	Prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP)	Not available as not recommended for use in NHS Scotland. 'Available within ultra orphan pathway while further evidence on effectiveness is generated	<a href="#">183</a> <a href="#">Protocol</a>	March 2021
Afatinib (Giotrif®) 174/16	As monotherapy for the treatment of locally advanced or metastatic non small cell lung cancer of squamous histology progressing on or after platinum based chemotherapy.	Not available as not recommended for use in NHS Scotland	<a href="#">156</a>	Sep 2016
Afatinib (Eylea®) (954/14)	For adults for treatment of visual impairment due to macular oedema	Hospital Only	<a href="#">137</a>	Apr/May 2014
Afatinib (Giotrif®) (920/13)	Adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s)	Hospital Only (Oncology)	<a href="#">136</a>	Mar/Apr 2014

amivantamab (Rybrevant) SMC2638	as monotherapy for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) Exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy.	Not available as not recommended for use in NHS Scotland	196	February 2024
Aflibercept 40mg/ml solution for injection (Eylea®) SMC 1186/16	For adults for the treatment of visual impairment due to myopic choroidal neovascularisation (myopic CNV).	Available in line with local guidance.	<a href="#">158</a>	Dec 2016
Aflibercept (Eylea®) (1074/15)	For adults for the treatment of visual impairment due to macular oedema secondary to branch retinal vein occlusion	Formulary Hospital Only  Ophthalmology Specialist Formulary List	<a href="#">151</a>	Sep/Oct 2015
Aflibercept (Eylea®) (1003/14)	For adults for the treatment of visual impairment due to diabetic macular oedema (DMO). SMC restriction: treatment of visual impairment due to DMO in adults with best corrected visual acuity (BCVA) 75 Early Treatment Diabetic Retinopathy Study (ETDRS) letters or less at baseline	Formulary 2nd line choice for DMO in patients unresponsive to ranibizumab treatment Hospital Only	<a href="#">143</a>	Nov/Dec 2014
Aflibercept (Zaltrap®) (878/13)	Metastatic colorectal cancer (mCRC)	Hospital Only (Oncology)	<a href="#">136</a> <a href="#">129</a>	Mar/Apr 2014 Aug/Sep 2013
Aflibercept (Eylea®) (954/14)	For adults for treatment of visual impairment due to macular oedema	Hospital Only 2nd line choice	<a href="#">137</a>	Apr/May 2014
Aflibercept (Eylea®) (857/13)	Neovascular (wet) age-related macular degeneration	Hospital Only (Ophthalmology Specialist List)	<a href="#">127</a> <a href="#">139</a>	May 2013 Jun/Jul 2014



Agomelatine (Valdoxan®) (564/09)	Major depressive disorders in adults	Not recommended	<a href="#">99</a> <a href="#">93</a>	Aug/Sep 2010 Oct/Nov 2009
Aflibercept solution for injection in pre-filled syringe (Eylea®) SMC2612	In preterm infants for the treatment of retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 2+ or 3+) or AP-ROP (aggressive posterior ROP) disease.	Not recommended	<a href="#">194</a>	September 2024
Albiglutide 30mg and 50mg pre-filled pen (Eperzan®) SMC No. 1024/15	Treatment of type 2 diabetes mellitus in adults to improve glycaemic control in combination with other glucose-lowering medicinal products including basal insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.  SMC Restriction: an alternative once weekly glucagon-like peptide-1 (GLP-1) agonist for use in combination with oral anti-diabetic agents as a third-line pre-insulin treatment option.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	<a href="#">153</a> <a href="#">154</a>	Jan/Feb 2016 May 2016
Alectinib 150mg hard capsules (Alecensa®) SMC No 2012 following a full submission assessed under orphan medicine process	As monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). Alectinib, compared with another tyrosine kinase inhibitor, significantly improved progression-free survival in treatment-naïve adults with advanced or recurrent ALK-positive NSCLC.	Available in line with National Guidance	<a href="#">170</a>	Sep 2018
Alectinib hydrochloride, 150mg hard capsules (Alecensa®) SMC No: (1257/17)	As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase positive advanced non-small cell lung cancer previously treated with crizotinib	Not available as not recommended for use in NHS Scotland	<a href="#">162</a>	Aug 2017
Alendronic acid 70mg effervescent tablet (Binosto®)	Treatment of postmenopausal osteoporosis.	Available in line with National	<a href="#">155</a>	Jun 2016

SMC 1137/16	SMC Restriction: for use in patients who are unable to swallow tablets where alendronic acid is the appropriate treatment choice.	Guidance		
Alemtuzumab (Lemtrada®) (959/14)	For adult patients with relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features.	<a href="#">Available in line with local guidance for prescribing</a>	<a href="#">140</a>	Jul/Aug 2014
Alemtuzumab (MabCampath®) (494/08)	B-cell chronic lymphocytic leukaemia (B-LL)	Hospital Only	<a href="#">82</a>	Aug/Sep 2008
Alendronate/colecalciferol (Fosavance®)	Postmenopausal osteoporosis	Non-formulary	<a href="#">54</a>	2005
Alglucosidase alfa (Myozyme®) 9352/07)	Pompe disease	Not recommended	<a href="#">67</a>	Mar 2007
alirocumab 75mg / 150mg solution for injection in pre-filled pen (Praluent®) SMC2201	In adults with established atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors: <ul style="list-style-type: none"> <li>• in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or,</li> <li>• alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.</li> </ul>	Not available as not recommended for use in NHS Scotland	<a href="#">175</a>	Aug 2019
Alirocumab 75mg and 150mg solution for injection in prefilled pen (Praluent®)	Adults with primary hypercholesterolaemia (heterozygous familial and non familial) or mixed dyslipidaemia, as an adjunct to diet: in combination with a statin and other lipid lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of statin or, alone or in combination with other lipid lowering therapies in patients who are statin intolerant or for whom a statin is contra-indicated.	Available in line with local guidance for prescribing  <a href="#">(Link to Formulary)</a>	<a href="#">156</a>	Sep 2016

Aliskiren (Razilex®) (462/08)	Essential hypertension	Not recommended	<a href="#">114</a> <a href="#">95</a> <a href="#">86</a> <a href="#">79</a>	Feb 2012 Feb/Mar 2010 Jan 2009 May 2008
Alitretinoin (Toctino®) (538/09)	Severe chronic hand eczema	Hospital Only (Dermatology Clinic)	<a href="#">87</a>	Mar 2009
Alpelisib 50mg, 150mg, 200mg film-coated tablets (Piqray®) SMC2481	In combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine-based therapy. The addition of alpelisib to fulvestrant significantly increased progression-free survival in patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer with PIK3CA mutation.	Not available as not recommended for use in NHS Scotland		
Alogliptin (Vipodomet®) (998/14)	Adult patients aged 18 years and older with Type 2 diabetes mellitus	Non-formulary - absence of clinician demand	<a href="#">142</a>	Oct/Nov 2014
Alogliptin (Vipidia®) (937/14)	Type 2 diabetes mellitus in adults	Non-formulary - absence of clinician demand	<a href="#">141</a> <a href="#">136</a>	Sep/Oct 2014 Mar/Apr 2014
Alteplase (Actilyse Cathflo®) (714/11)	Acute ischaemic stroke	Hospital Only (NW Stroke unit/A&E, PRI Gen Med) Stroke specialist list	<a href="#">118</a>	July 2012
Alteplase (Actilyse Cathflo®) (717/11)	Thrombolytic treatment of occluded central venous access devices	Non-formulary - absence of clinician demand	<a href="#">113</a> <a href="#">109</a>	Jan 2012 Sep 2011
Alteplase (Actilyse®) (87/04)	Acute ischaemic stroke	Hospital Only	<a href="#">37</a>	2004

Ambrisentan (Volibris®) (511/08)	Class II and III pulmonary arterial hypertension		<a href="#">84</a>	Nov 2008
Amifampridine (Firdapse®) (660/10)	Lambert-Eaton Myasthenic Syndrome (LEMS) in adults	Not recommended	<a href="#">119</a> <a href="#">100</a>	Aug/Sep 2012 Oct/Nov 2010
Amikacin liposomal nebuliser dispersion 590mg (Arikayce®) SMC2432	Treatment of non-tuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium Complex (MAC) in adults with limited treatment options who do not have cystic fibrosis. Consideration should be given to official guidance on the appropriate use of antibacterial agents. The addition of amikacin liposomal nebuliser dispersion to standard oral guideline-based therapy for MAC NTM lung infections significantly increased the proportion of patients achieving sputum culture conversion at 6 months and post-treatment at 3 months.	Not routinely available as local implementation plans are being developed or the ADTC is waiting for further advice from local clinical experts - decision expected by May 2022	<a href="#">188</a>	April 2022
Amikacin liposomal nebuliser dispersion 590mg (Arikayce®) SMC2369	Indication under review: Treatment of non-tuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium Complex (MAC) in adults with limited treatment options who do not have cystic fibrosis. Consideration should be given to official guidance on the appropriate use of antibacterial agents. The addition of amikacin liposomal nebuliser dispersion to standard oral guideline-based therapy for MAC NTM lung infections significantly increased the proportion of patients achieving sputum culture conversion at 6 months and post-treatment at 3 months. The submitting company's justification of the treatment's cost in relation to its health benefits was not sufficient and in addition the company did not present a sufficiently robust economic analysis to gain acceptance by SMC.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	<a href="#">187</a>	Dec 2021
5-aminolevulinic acid 8mg medicated plaster (Alacare®)	Single use treatment of mild actinic keratoses lesions with a maximum diameter of 1.8 cm on the face and scalp	Not routinely available as local clinical experts do not wish to	<a href="#">185</a>	July 2021

SMC2353	(hairless areas).	add the medicine to the formulary at this time or there is a local preference for alternative medicines		
5-aminolaevulinic acid (Ameluz®) (811/12)	Treatment of actinic keratosis of mild to moderate intensity on the face and scalp	Hospital Only (Dermatology Clinic)	<a href="#">123</a>	Jan 2013
amivantamab (Rybrevant) SMC2638	as monotherapy for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) Exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy.	Not available as not recommended for use in NHS Scotland		
Amlodipine/valsartan (Exforge®) (350/07)	Hypertension	Non-formulary	<a href="#">67</a>	Mar 2007
Anagrelide (Xagrid®)	Thrombocythaemia	Hospital Only	<a href="#">54</a> <a href="#">50</a>	2005
Anakinra 100mg solution for injection in a pre-filled syringe (Kineret®) SMC2449	Treatment of Familial Mediterranean Fever (FMF). Kineret should be given in combination with colchicine, if appropriate.	Not available as not recommended for use in NHS Scotland	<a href="#">188</a>	April 2022
Anakinra 100mg/0.67mL solution for injection in pre-filled syringe (Kineret®) SMC2104	In adults, adolescents, children and infants aged eight months and older with a body weight of 10kg or above for the treatment of Still's disease, including Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still's Disease (AOSD), with active systemic features of moderate to high disease activity, or in patients with continued disease activity after treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or glucocorticoids. Anakinra can be given as monotherapy or in combination with other anti-inflammatory drugs and disease-modifying anti-rheumatic drugs (DMARDs).  Anakinra was superior to placebo in achieving a modified	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	<a href="#">172</a>	Dec 2018

	American College of Rheumatology paediatric (mACRpedi) 30 response in patients with SJIA reliant on corticosteroids for disease control. Anakinra and DMARDs were associated with a similar remission rate in patients with AOSD following eight weeks of treatment.			
Anakinra (Kineret®) 1116/15	Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above, including: <ul style="list-style-type: none"> <li>• Neonatal-Onset Multisystem inflammatory Disease (NOMID) / Chronic Infantile Neurological, Cutaneous, Articular Syndrome (CINCA)</li> <li>• Muckle-Wells Syndrome (MWS)</li> <li>• Familial Cold Autoinflammatory Syndrome (FCAS)</li> </ul>	Not Recommended	<a href="#">153</a>	Jan/Feb 2016
Anakinra (Kineret®)	Rheumatoid arthritis			2002
Anastrozole (Arimidex®)	ER positive early breast cancer		<a href="#">63</a> <a href="#">53</a> <a href="#">37</a>	2006 2005 2004
Andexanet alfa 200 mg powder for solution for infusion (Ondexxya®) SMC2273	For adult patients treated with a direct factor Xa (FXa) inhibitor (apixaban or rivaroxaban) when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding. In an open-label single-arm study andexanet alfa reduced anti-FXa activity and improved haemostatic efficacy in adults with major bleeds.	Available in line with local guidance for prescribing	<a href="#">181</a>	November 2020
Anidulafungin (Ecalta®) (465/08)	Invasive candidiasis	Hospital Only	<a href="#">85</a> <a href="#">84</a>	Dec 2008 Nov 2008

			<a href="#">80</a>	June 2008
apalutamide 60mg film-coated tablets (Erleada®) SMC2579	in adults for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.		
Apalutamide 60mg film-coated tablets (Erleada®) SMC2472	Treatment of adults with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (ADT).  Apalutamide plus ADT significantly improved radiographic progression-free survival (rpfs) and overall survival compared with placebo plus ADT in adults with mhspc.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	<a href="#">191</a>	November 2022
Apalutamide 60mg film-coated tablets (Erleada®) SMC2323	In adult men for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy.	Not available as not recommended for use in NHS Scotland	<a href="#">183</a>	March 2021
Apalutamide 60mg film-coated tablets (Erleada®) SMC2579	In adults for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	<a href="#">194</a>	September 2023
Apixaban 2.5mg and 5mg film-coated tablets (Eliquis®) (836/13)	Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAf),	Formulary (Restricted to patients who have poor INR control on warfarin or with allergy to, or uncontrollable side effects from coumarin anticoagulants)	<a href="#">125</a>	Mar/Apr 2013
Apixaban, 2.5mg & 5mg, film-coated tablets (Eliquis®)	Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT and PE in	Formulary - Amber	<a href="#">146</a>	Mar 2015

(1029/15)	adults.	2nd line choice for DVT/PE as an alternative to rivaroxaban		
Apixiban (Eliquis®) (741/11)	Prevention of VTE	Not recommended	<a href="#">113</a>	Jan 2012
Apremilast (Otezla®) (1052/15)	For the treatment of moderate to severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including ciclosporin, methotrexate or psoralen and ultraviolet-A light (PUVA).	Hospital Only Dermatology Clinic Dermatology Specialist List	<a href="#">149</a>	Jun/Jul 2015
Apremilast (Otezla®) (1053/15)	For us alone or in combination with disease modifying anti-rheumatic drugs (DMARDs), for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy.	Non Formulary Pending local agreement	<a href="#">149</a>	Jun/Jul 2015
Aprepitant (Emend®) 80mg, 125mg hard capsules , Aprepitant (Emend®) 125mg powder for oral suspension SMC No. (1252/17)	As part of combination therapy, for the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy in children, toddlers and infants from the age of six months to <12 years (powder for oral suspension) and adolescents from the age of 12 years to 17 years (hard capsules).  SMC has previously accepted aprepitant for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based chemotherapy in adults. The marketing authorisation has since been extended to cover prevention of nausea and vomiting in adults associated with highly emetogenic non-cisplatin based chemotherapy. SMC does not plan to assess this minor licence extension.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	<a href="#">163</a>	Sep 2017
Aprepitant, 80mg, 125mg hard capsules and 125mg powder for	As part of combination therapy, for the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in infants, toddlers and children from	Available in line with local guidance for prescribing	<a href="#">162</a>	Aug 2017



oral suspension (Emend®) SMC No (1241/17)	the age of six months to less than 12 years (powder for oral suspension) and adolescents from the age of 12 years to 17 years (hard capsules).			
Aprepitant (Emend®)	Prevention of cisplatin-induced nausea and vomiting	Hospital Only	<a href="#">46</a>	2004
Aprepitant (Emend®) (242/06)	Prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy	Not recommended	<a href="#">112</a> <a href="#">56</a>	Dec 2011 2006
Argatroban (Exembo®) (812/12)	Anticoagulation in adult patients with heparin-induced thrombocytopenia type II who require parenteral antithrombotic therapy	Hospital Only (2nd line)	<a href="#">129</a> <a href="#">122</a>	Aug/Sep 2013 Dec 2012
Aripiprazole (Abilify Maintena®) (962/14)	Schizophrenia in adults	Hospital Only	<a href="#">138</a>	May/June 2014
Aripiprazole (Abilify®) (891/13)	Moderate to severe manic episodes in Bipolar 1 Disorder in adolescents aged 13 years and older	Hospital Only Child & Adolescent Mental Health Services (CAMHS)	<a href="#">130</a>	Sept/Oct 2013
Aripiprazole (Abilify®) (630/10)	Schizophrenia in adolescents 15 years and older	Hospital Only (Child/adolescent psychiatry)	<a href="#">99</a> <a href="#">85</a> <a href="#">52</a> <a href="#">43</a>	Aug/Sep 2010 Dec 2008 2005 2004
Aripiprazole (Abilify®) orodispersible tablets	Moderate to severe manic episodes in bipolar 1 disorder		<a href="#">90</a> <a href="#">82</a>	June 2009 Aug/Sep 2008
Asciminib 20mg and 40mg film-coated tablets (Scemblix®) SMC2482	For the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase (Ph+ CML-CP), previously treated with two or more tyrosine kinase inhibitors (TKIs), and without a known T315I mutation.  In an open-label, phase III study, asciminib was associated	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	<a href="#">191</a>	Nov 2022

	with significantly higher major molecular response rates than another TKI in patients with Ph+ CML-CP who had received at least two previous TKIs and did not have a T315I mutation.			
Arsenic trioxide 1mg/mL concentrate for solution for infusion (Trisenox®) SMC2181	In combination with all-trans-retinoic acid (ATRA [tretinoin]) for the induction of remission, and consolidation in adult patients with newly diagnosed, low-to-intermediate risk acute promyelocytic leukaemia (APL) (white blood cell count $\leq 10 \times 10^3/\mu\text{l}$ ), characterised by the presence of the t(15;17) translocation and/or the presence of the Pro Myelocytic Leukaemia/Retinoic-Acid-Receptor-alpha (PML/RAR-alpha) gene.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	<a href="#">176</a>	Oct 2019
Arsenic trioxide 1mg/mL concentrate for solution for infusion (Trisenox®) SMC2025	In combination with all-trans-retinoic acid (ATRA [tretinoin]) for the induction of remission, and consolidation in adult patients with newly diagnosed, low-to-intermediate risk acute promyelocytic leukaemia (APL) (white blood cell count, $\leq 10 \times 10^3/\mu\text{l}$ ), characterised by the presence of the t(15;17) translocation and/or the presence of the Pro Myelocytic Leukaemia/Retinoic-Acid-Receptor-alpha (PML/RAR-alpha) gene	Not available as not recommended for use in NHS Scotland	<a href="#">173</a>	Mar 2019
Asenapine (Sycrest®) (762/12)	Treatment of moderate to severe manic episodes associated with bipolar I disorder in adults.	Not recommended	<a href="#">116</a>	Apr/May 2012
Asfotase alfa 40mg/mL and 100mg/mL solution for injection (Strensiq®) SMC 2433		Not available as not recommended for use in NHS Scotland	<a href="#">188</a>	April 2022
Ataluren 125mg, 250mg, and 1,000mg granules for oral suspension (Translarna®) SMC2327	Indication under review: Treatment of Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 2 years and older. The presence of a nonsense mutation in the dystrophin gene should be determined by genetic testing.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	<a href="#">184</a>	May 2021

Ataluren 125mg, 250mg, 1,000mg granules for oral suspension (Translarna®) SMC 1131/16	Treatment of Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 5 years and older.	Not available as not recommended for use in NHS Scotland	<a href="#">155</a>	June 2016
Atazanavir/cobistat (Evotaz®) (1098/15)	In combination with other antiretroviral medicinal products for the treatment of HIV-1 infected adults without known mutations associated with resistance to atazanavir.	Formulary - Hospital Use Only (HIV Clinic)	<a href="#">152</a>	Nov/Dec 2015
Atazanavir (Reeyataz®) (656/10)	HIV	Hospital Only (HIV Clinic)	<a href="#">101</a> <a href="#">86</a> <a href="#">85</a> <a href="#">45</a> <a href="#">44</a>	Dec 10/Jan 2011 Jan/Feb 2009 Dec 2008 2004
Atezolizumab 840mg and 1,200mg concentrate for solution for infusion (Tecentriq®) SMC2492	As monotherapy as adjuvant treatment following complete resection for adult patients with Stage II to IIIA (7th edition of the UICC/AJCC staging system) non-small cell lung cancer (NSCLC) whose tumours have PD-L1 expression on $\geq 50\%$ of tumour cells and whose disease has not progressed following platinum-based adjuvant chemotherapy. In an open-label, randomised, phase III study, disease-free survival in patients with stage II to IIIA NSCLC, was significantly longer in patients whose tumours had PD-L1 expression on $\geq 1\%$ of tumour cells and numerically longer in patients whose tumours had PD-L1 expression on $\geq 50\%$ of tumour cells with atezolizumab compared with best supportive care. All patients prior to randomisation had disease that had not progressed following adjuvant platinum-	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	<a href="#">190</a>	August 2022

	based chemotherapy, following complete resection.			
Atezolizumab 840mg and 1,200mg concentrate for solution for infusion (Tecentriq®) SMC2379		Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	<a href="#">188</a>	April 2022
Atezolizumab (Tecentriq®) 1,200mg concentrate for solution for infusion SMC2349	In combination with bevacizumab for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.	Available in line with local guidance for prescribing	<a href="#">186</a>	Sept 2021
Atezolizumab 1,200 mg concentrate for solution for infusion (Tecentriq®) SMC2279	Atezolizumab, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).	Available in line with national guidance	<a href="#">182</a>	January 2021
Atezolizumab 840mg concentrate for solution for infusion (Tecentriq®) SMC2267	Atezolizumab in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have programmed death-ligand 1 [PD-L1] expression $\geq 1\%$ and who have not received prior chemotherapy for metastatic disease.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	<a href="#">182</a>	January 2021
Atezolizumab 1,200mg concentrate for solution for infusion (Tecentriq®) SMC2208	In combination with bevacizumab, paclitaxel and carboplatin, for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC). In patients with epidermal growth factor receptor (EGFR) mutant or anaplastic lymphoma kinase (ALK)-positive NSCLC, atezolizumab in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	<a href="#">178</a>	Feb 2020
Atezolizumab 1,200mg concentrate for solution for infusion	In combination with nab-paclitaxel and carboplatin for the first-line treatment of adult patients with metastatic non-	Not available as not recommended for use in NHS	<a href="#">178</a>	Feb 2020

(Tecentriq®) SMC 2254	squamous non-small cell lung cancer (NSCLC) who do not have EGFR mutant or ALK-positive NSCLC.	Scotland		
Atezolizumab 1,200mg concentrate for solution for infusion (Tecentriq®) SMC2103	As monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma after prior platinum-containing chemotherapy.	Not available as not recommended for use in NHS Scotland	<a href="#">172</a>	Dec 2018
Atezolizumab 1,200mg concentrate for solution for infusion (Tecentriq®) SMC No 1336/18	As monotherapy for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. Patients with epidermal growth factor receptor (EGFR) activating mutations or anaplastic lymphoma kinase (ALK)-positive tumour mutations should also have received targeted therapy before receiving atezolizumab. SMC restriction: treatment with atezolizumab is subject to a two-year clinical stopping rule.	Not routinely available as local implementation plans are being developed or the ADTC is waiting for further advice from local clinical experts- decision expected by October 2018	<a href="#">170</a>	Sep 2018
Atezolizumab 1,200mg concentrate for solution for infusion (Tecentriq®) SMC No 1297/18	As monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma after prior platinum-containing chemotherapy or who are considered cisplatin ineligible.	Not available as not recommended in NHS Scotland	<a href="#">168</a>	May 2018
atidarsagene autotemcel 2 to 10 x 10 <sup>6</sup> cells/mL dispersion for infusion (Libmeldy®) SMC2413	treatment of metachromatic leukodystrophy (MLD) characterized by biallelic mutations in the arylsulfatase A (ARSA) gene leading to a reduction of the ARSA enzymatic activity	Available from a specialist centre in another NHS Board	<a href="#">189</a>	May 2022
atogepant tablets (Aquipta®) SMC2599	"for the prophylaxis of migraine in adults who have at least 4 migraine days per month.	Not routinely available as local implementation plans are being developed	<a href="#">195</a>	December 2023
Atomoxetine (Strattera®) (909/13)	ADHD - adults	Formulary (GP under direction of Mental Health Specialist)	<a href="#">143</a> <a href="#">132</a>	Nov/Dec 2014 Nov/Dec 2013

Atomoxetine oral solution 4mg/mL (Strattera®) SMC No. 1107/15	Treatment of attention-deficit/hyperactivity disorder (ADHD) in children of 6 years and older, in adolescents and in adults as part of a comprehensive treatment programme. Treatment must be initiated by a specialist in the treatment of ADHD, such as a paediatrician, child/adolescent psychiatrist, or psychiatrist. Diagnosis should be made according to current DSM criteria or the guidelines in ICD.  SMC Restriction: to use in patients who are unable to swallow capsules.	Formulary  Amber - can be prescribed by General Practice under direction of a specialist	<a href="#">153</a>	Jan/Feb 2016
Atomoxetine (Strattera®)	ADHD - children of 6 years and older or in adolescents	Specialist treatment pathway - GPs may prescribe under the direction of a specialist in childhood behavioural disorders	<a href="#">52</a> <a href="#">49</a>	2005
Atorvastatin (Lipitor®) (766/12)	Adjunct to diet for reduction of elevated total cholesterol, LDL-cholesterol, apolipoprotein B, and triglycerides in adults, adolescents and children aged 10 years or older with primary hypercholesterolaemia including familial hypercholesterolaemia or combined hyperlipidaemia when response to diet and other nonpharmacological measures is inadequate; Reduction of total-C and LDL-C in adults with homozygous familial hypercholesterolaemia as an adjunct to other lipid-lowering treatments or if such treatments are unavailable; Prevention of cardiovascular events in adult patients estimated to have a high risk for a first cardiovascular event, as an adjunct to correction of other risk factors.	GPs may prescribe under the direction of a paediatric tertiary centre	<a href="#">116</a>	Apr/May 2012
Atorvastatin (Lipitor®)	Hypercholesterolaemia in children		<a href="#">54</a>	2005
Autologous anti-CD19-transduced CD3+ cells (KTE-X19) 0.4 to 2 × 10 <sup>8</sup> cells dispersion for infusion	The treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after two or more lines of systemic therapy including a Bruton's tyrosine kinase (BTK)	Available from a specialist centre in another NHS Board	<a href="#">186</a>	Sept 2021

(Tecartus®) SMC2351	inhibitor.			
Avacopan hard capsules (Tavneos®) SMC2578	In combination with a rituximab or cyclophosphamide regimen, for the treatment of adult patients with severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA).	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	<a href="#">195</a>	December 2023
avalglucosidase alfa 100mg powder for concentrate for solution for infusion (Nexviadyme®) SMC2546	long-term enzyme replacement therapy for the treatment of patients with Pompe disease (acid $\alpha$ -glucosidase deficiency)	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.		
Avanafil (Spedra®) (980/14)	Erectile dysfunction in adult men.	Not recommended	<a href="#">139</a> <a href="#">151</a>	June/July 2014 Sep/Oct 2015
Avalglucosidase alfa 100mg powder for concentrate for solution for infusion (Nexviadyme®) SMC2546	Long-term enzyme replacement therapy for the treatment of patients with Pompe disease (acid $\alpha$ -glucosidase deficiency)	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	<a href="#">194</a>	September 2023
avapritinib 100mg, 200mg and 300mg film-coated tablets (Ayvakyat®) SMC2424`	As monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) harbouring the platelet-derived growth factor receptor alpha (PDGFRA) D842V mutation.		<a href="#">187</a>	Dec 2021
Avatrombopag 20mg film-coated tablets (Doptelet®) SMC2345	Treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. Corticosteroids or immunoglobulins). SMC restriction: to use in patients with severe symptomatic ITP or a high risk of bleeding.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative	<a href="#">186</a>	Sept 2021

		medicines		
Avatrombopag 20mg film-coated tablets (Doptelet®) SMC2296	Treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	<a href="#">182</a>	January 2021
Avelumab 20mg/ml concentrate for solution for infusion (Bavencio®)	As monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are progression-free following platinum-based chemotherapy.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	<a href="#">186</a>	Sept 2021
Avelumab 20mg/mL concentrate for solution for infusion (Bavencio®) SMC2248	In combination with axitinib for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC). Avelumab plus axitinib, compared with a vascular endothelial growth factor (VEGF)-targeting tyrosine-kinase inhibitor (TKI), improved progression-free survival in adults with advanced RCC.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time	<a href="#">181</a>	November 2020
Avelumab 20mg/mL concentrate for solution for infusion (Bavencio®) SMC No 1315/18	As monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma (mMCC).	Available in line with national guidance	<a href="#">169</a>	July 2018
Aviptadil/phentolamine 25 micrograms/2mg solution for injection (Invicorp®) SMC No 1284/17	For the symptomatic treatment of erectile dysfunction in adult males due to neurogenic, vasculogenic, psychogenic, or mixed aetiology.		<a href="#">166</a>	Feb 2018
Axicabtagene ciloleucel dispersion for infusion (Yescarta®) SMC2646	Treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after three or more lines of systemic therapy.	Not available as not recommended for use in NHS Scotland	196	Feb 2024



Axicabtagene ciloleucel 0.4 – 2 x 10 <sup>8</sup> cells dispersion for infusion (Yescarta®) SMC2189	Treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) and primary mediastinal large B cell lymphoma (PMBCL), after two or more lines of systemic therapy.	Available from a specialist centre in another NHS Board.	<a href="#">177</a>	Dec 2019
Axicabtagene ciloleucel 0.4 – 2 x 10 <sup>8</sup> cells dispersion for infusion (Yescarta®) SMC2114	Treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) and primary mediastinal large B cell lymphoma (PMBCL), after two or more lines of systemic therapy.	Not available as not recommended for use in NHS Scotland	<a href="#">174</a>	May 2019
Axicabtagene ciloleuce SMC2646	Treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after three or more lines of systemic therapy.		Awaiting publication	January 2024
Axicabtagene ciloleucel dispersion for infusion (Yescarta) SMC2628	For the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.		Awaiting publication	February 2024
Axitinib (Inlyta®) (855/13)	Advanced renal cell carcinoma (RCC)	Hospital Only (Oncology)	<a href="#">132</a> <a href="#">127</a>	Nov/Dec 2013 May 2013
azacitidine film-coated tablets (Onureg®) SMC2533	maintenance therapy in adult patients with acute myeloid leukaemia who achieved complete remission or complete remission with incomplete blood count recovery following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, haematopoietic stem cell transplantation.	Available in line with national guidance		
Azacitidine (Vidaza®) 1175/16	Treatment of adult patients aged 65 years or older who are not eligible for haematopoietic stems cell transplantation (HSCT) with acute myeloid leukaemia (AML with >30% marrow blasts according to World Health Organisation classification).	Not available as not recommended for use in NHS Scotland	<a href="#">156</a>	Sep 2016
Azacitidine (Vidaza®) (589/09)	Adult patients not eligible for haematopoietic SCT with	Non-formulary - pending	<a href="#">116</a>	Apr/May 2012

	intermediate-2 and high risk MDS, CMML or AML.	protocol	<a href="#">110</a> <a href="#">96</a>	Oct 2011 Apr/May 2010
Azacitidine film-coated tablets (Onureg®) SMC2533	Maintenance therapy in adult patients with acute myeloid leukaemia who achieved complete remission or complete remission with incomplete blood count recovery following induction therapy with or without	Available in line with national guidance	<a href="#">194</a>	September 2023
Azelaic acid (Finacea® 15% Gel) (359/07)	Papulopustular rosacea	Non-formulary	<a href="#">68</a>	May 2007
Azelastine hydrochloride (Dymista® nasal spray) (921/13)	For the relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.	Formulary	<a href="#">144</a> <a href="#">142</a> <a href="#">133</a>	Jan/Feb 2015 Oct/Nov 2014 Dec 13/Jan 14
Azilsartan medoxomil (Edarbi®) (803/12)	Treatment of essential hypertension in adults	Not recommended	<a href="#">119</a>	Aug/Sep 2012
Azithromycin (Zedbac®) (950/14)	CAP and PID	Hospital Only (Under direction of ID or Microbiology)	<a href="#">137</a>	Apr/May 2014
Azithromycin dihydrate (Azyter®) (804/12)	Conjunctivitis caused by susceptible strains	Not recommended	<a href="#">119</a>	Aug/Sep 2012
Aztreonam lysine (Cayston®) (753/12)	Suppressive therapy of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with CF aged 18 years and older	Formulary (GP under direction of specialist in Paediatric or Adult CF Team)  (Respiratory Specialist List)	<a href="#">145</a> <a href="#">115</a>	Feb 2015 Mar/Apr 2012

Updated: 15th March 2024

[Back to top](#)

[Back to homepage](#)